AbbVie To Build On Relationship With Calibr Via Five-Year Extension

 
• By Joseph Haas

Deal Snapshot: Previously partnered on CAR-T therapies for cancer and COVID-19 antivirals, AbbVie and Scripps’ discovery unit Calibr unveil a five-year extension, including new targets and preclinical candidates.

AbbVie exterior
AbbVie continues its discovery alliance with Calibr/Scripps Research • Source: Alamy

More from Deals

More from Business